09.17.20 -- Sandoz President: Managing The COVID-19 Biologics Supply Chain

In this Q&A, Carol Lynch, president, U.S. and head of North America for Sandoz, discusses the supply challenges she’s observed in the biologics space throughout the current pandemic and the efforts biosimilar makers should be taking to meet patients’ needs and prepare for future supply disruptions.

The Federal Circuit recently issued Rule 36 judgments in two separate BPCIA cases: Genentech v. Amgen and Janssen v. Celltrion. Because the Federal Circuit decided both appeals without opinion, several open questions remain unresolved regarding BPCIA litigation. This two-part article explores those questions, starting with Genentech v. Amgen.

Many of the articles on this site are focused on how manufacturers can or are working to improve biosimilar uptake. But other stakeholders are aware of the power they, too, hold in improving uptake. One oncologist highlights how she and fellow oncologists are educating stakeholders and drawing greater government attention to payer policy and biosimilar use.